SCHEMBL7606891

SCHEMBL7606891

O=C(O)CCC(OP(=O)(O)CCc1cccc2[nH]ccc12)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
GLS O94925 2/20 0.36
FOLH1 Q04609 1/20 0.34
HTR2A P28223 1/20 0.34
HDAC1 Q13547 4/20 0.34
HDAC2 Q92769 4/20 0.34
HDAC6 Q9UBN7 3/20 0.34
HDAC3 O15379 2/20 0.34
HDAC4 P56524 2/20 0.34
HDAC7 Q8WUI4 2/20 0.34
HDAC10 Q969S8 2/20 0.34
HDAC11 Q96DB2 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
HDAC9 Q9UKV0 2/20 0.34
HDAC5 Q9UQL6 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
MCL1 Q07820 1/20 0.32
HPGDS O60760 1/20 0.32
DAO P14920 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5054319 0.89 PARP1 (0.38) PARP1GLSFOLH1HDAC1HDAC2
SCHEMBL5057556 0.86 SMN1; SMN2 (0.46) SMN1; SMN2KDM4EAPAF1POLBMAPT
SCHEMBL5054580 0.83 FFAR1 (0.43) FOLH1MCL1
SCHEMBL8058845 0.81 HPGDS (0.37) PARP1GLSHDAC1HDAC2HDAC6
SCHEMBL5057842 0.80 ALDH1A1 (0.48) SMN1; SMN2KDM4EAPAF1POLBMAPT
SCHEMBL7606043 0.80 HDAC1 (0.36) PARP1FOLH1HDAC1HDAC2HDAC6
SCHEMBL5057873 0.78 FOLH1 (0.43) FOLH1MCL1
SCHEMBL5053364 0.77 SMN1; SMN2 (0.49) SMN1; SMN2KDM4EAPAF1POLBMAPT
SCHEMBL5052948 0.77 FOLH1 (0.42) FOLH1MCL1
SCHEMBL8520179 0.77 SRC (0.39) PARP1GLSHDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002514184-A 2002-05-14 JP claimed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP claimed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed